Physicochemical Properties
| CAS # | 2919303-26-5 |
| Appearance | Typically exists as solid at room temperature |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | IC50: 0.20 μM (PAN)[1] KD: 56.02 nM (PAN)[1] |
| ln Vitro | Influenza virus-IN-6 (Compound 35) exhibits anti-influenza virus activity after 48 hours, with EC50s of 1.28 ± 0.35, 1.12 ± 0.65, 0.76 ± 0.11, and Flu B against H1N1, H5N1, H3N2, and Flu B in MDCK cells, respectively. 0.43 ± 0.06 μM[1]. Influenza virus-IN-6 (5–20 μM; 24 h) impacts viral adsorption, but not viral particles, cells, or replication [1]. Influenza virus-IN-6 suppresses the activity of influenza virus polymerase at 2.5–10 μM for 24 hours [1]. In liver microsomes, intestine S9-UDPGA, and mouse plasma, influenza virus-IN-6 exhibits good stability [1]. |
| ln Vivo | Compound 35 (7.5-30 mg/kg/d; intraperitoneally; twice daily for 7 days) effectively shields mice against influenza virus infection [1]. The influenza virus-IN-6 (Compound 35) pharmacokinetic (PK) profile in vivo after a single dose in rats (n = 5)a[1] parameter IV (2 mg/kg) PO (10 mg/kg) IP (15 mg/kg) T1/2 (h) 0.33 ± 0.07 0.82 ± 0.16 1.07 ± 0.25 Tmax (h) NA 0.52 0.45 Cmax (ng/mL) 1586.55 ± 366.48 92.20 ± 36.25 889.52 ± 233.17 AUC0-t (h · ng/mL) 536.45 ± 58.72 164.30 ± 26.37 790.62 ± 188.31 CL (mL/min/kg) 53.76 ± 13.18 NA NA F % NA 6.13% 29.50% aIV stands for intravenous injection, IP for intraperitoneal injection, and PO for the gastrointestinal route. The half-life of a compound exposure in plasma is known as T1/2. The time it takes to focus to its maximum is known as Tmax. Cmax is the greatest concentration that has been measured. The area under the curve is known as AUC (0–t). The clearance is CL (mL/min/kg). The percentage of bioavailability is F%. |
| Cell Assay |
Western Blot Analysis[1] Cell Types: MDCK cells Tested Concentrations: 5, 10 and 20 μM Incubation Duration: 24 h Experimental Results: diminished nucleoprotein (NP) and matrix protein 2 (M2). RT-PCR[1] Cell Types: MDCK cells Tested Concentrations: 2.5, 5, 10 and 20 μM Incubation Duration: 24 h Experimental Results: diminished the expression of viral NP mRNA in a well-defined dose-dependent manner. Inhibited cRNA synthesis in a dose-dependent fashion. |
| Animal Protocol |
Animal/Disease Models: balb/c (Bagg ALBino) mouse:, H1N1 infection model[1] Doses: 0, 7.5, 15, and 30 mg/kg/d Route of Administration: intraperitoneal (ip)injection, twice per day for 7 days Experimental Results: demonstrated excellent anti-IAV activity in vivo at a dose of 30 mg/kg/d. Still demonstrated potent antiviral activity in vivo , with a survival ratio of approximately 60% against lethal virus infection in mice at 15 mg/kg/d. Animal/Disease Models: SD rats[1] Doses: 2, 10 or 15 mg/kg Route of Administration: IV, IP, or PO ( pharmacokinetic/PK Analysis) Experimental Results: demonstrated good pharmacokinetic/PK profiles. |
| References | [1]. Liao Y, et al. Identification of N- and C-3-Modified Laudanosoline Derivatives as Novel Influenza PAN Endonuclease Inhibitors. J Med Chem. 2022 Dec 15. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |